Covid 19 Research using Clinical Trials (Home Page)
Report for D000755: Anemia, Sickle Cell NIH
(Synonyms: Anemia, S, Anemia, Sickl, Anemia, Sickle Cell)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 A Longitudinal Survey Study on Living With Sickle Cell Disease in the COVID-19 Pandemic
Background: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their function. This results in a lifetime of complications that affect every organ system. People with SCD also are at greater risk for respiratory infections and lung problems. Researchers want to study how this population s stress, anxiety, fear, pain, sleep, and health care use are being affected by the COVID-19 pandemic. Objective: To study the extent and impact of life changes induced by the COVID-19 pandemic on people living with SCD in the U.S. Eligibility: People age 18 and older with SCD who live in the U.S. Design: Participants will complete a survey online. The questions will focus on the following: Medical history Mental and physical health Demographics Stress Resilience Health care use COVID-19 Beliefs about medical mistrust and participation in research. At the end of the survey, participants will be asked if they would like to take the survey again in the future. If they reply yes, then they will be contacted by the study team in 6 months to take the survey again. They may complete the survey again in 6 months, 12 months, and 18 months. The survey should take less than 40 minutes to complete. Participants data will be coded to protect their privacy. The coded data may be shared with other researchers....
NCT04417673 Isolation Anxiety Health Care Utilization Sickle Cell Disease Pain MeSH:Anemia, Sickle Cell
Primary Outcomes
Description: We will examine how theo COVID-19 pandemic impacts stress levels among individuals with sickle cell disease (SCD).
Measure: Stress Time: baseline, month 6, month 12, month 18Description: We will examine how the COVID-19 pandemic impacts anxiety levels among individuals with SCD.
Measure: Anxiety Time: baseline, month 6, month 12, month 18Description: This is an examination of questions relating to depression, which we will examine within our cohort.
Measure: Depressive symptomology Time: baseline, month 6, month 12, month 18Description: We will examine the association between clinical severity of SCD and an individual s response to the COVID-19 pandemic.
Measure: Pain episodes, and severity Time: baseline, month 6, month 12, month 18Description: We will investigate the impact of the COVID-19 pandemic on healthcare utilization for SCD individuals.
Measure: Healthcare utilization (primary care, emergency department, telehealth other) Time: baseline, month 6, month 12, month 18Secondary Outcomes
Description: We would like to explore how the attitudes about treatment and levels of trust will serve as mediating factors for the experiences of individuals with SCD during this pandemic.
Measure: Receptivity to future health recommendations and medical treatment(s). Time: baseline, month 6, month 12, month 18